EU's initial green-light to remdesivir might be granted in coming days - EMA
- Country:
- Belgium
The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorization for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in the coming days.
"It might be that a conditional market authorization can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorized.
ALSO READ
-
Belize Communities Take the Lead in New Push for Jobs, Skills and Stronger Futures
-
Hotter Years, More Cavities? Understanding Link Between Climate and Dental Health
-
Europe’s Rare Earth Wake-Up Call: Turning Years of Research Into Factories That Last
-
Lebanon’s Small Business Owners Build Skills and Market Links With EU and ILO Support
-
Poltava University Reopens With Safer, Greener Spaces for Nearly 3,000 Campus Users
Google News